View in EDS PDF Full Text

Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.

Saved in:
Bibliographic Details
Title: Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.
Authors: D'Huyvetter M; Precirix NV/SA, Brussels, Belgium; marleen.keyaerts@vub.be.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Vos J; Precirix NV/SA, Brussels, Belgium., Caveliers V; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Vaneycken I; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Heemskerk J; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Duhoux FP; Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium., Fontaine C; Department of Medical Oncology, UZ Brussel, Brussels, Belgium., Vanhoeij M; Department of Oncological Surgery, UZ Brussel, Brussels, Belgium., Windhorst AD; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Aa FV; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Hendrikse NH; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Eersels JLE; Precirix NV/SA, Brussels, Belgium.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Everaert H; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Gykiere P; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Devoogdt N; Precirix NV/SA, Brussels, Belgium.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Raes G; Precirix NV/SA, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; and.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Lahoutte T, Keyaerts M; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; marleen.keyaerts@vub.be.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.
Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Aug 01; Vol. 62 (8), pp. 1097-1105. Date of Electronic Publication: 2020 Dec 04.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33277400
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I Trial of <superscript>131</superscript>I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22D'Huyvetter+M%22">D'Huyvetter M</searchLink>; Precirix NV/SA, Brussels, Belgium; marleen.keyaerts@vub.be.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Vos+J%22">Vos J</searchLink>; Precirix NV/SA, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Caveliers+V%22">Caveliers V</searchLink>; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Vaneycken+I%22">Vaneycken I</searchLink>; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Heemskerk+J%22">Heemskerk J</searchLink>; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Duhoux+FP%22">Duhoux FP</searchLink>; Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Fontaine+C%22">Fontaine C</searchLink>; Department of Medical Oncology, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Vanhoeij+M%22">Vanhoeij M</searchLink>; Department of Oncological Surgery, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Windhorst+AD%22">Windhorst AD</searchLink>; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Aa+FV%22">Aa FV</searchLink>; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hendrikse+NH%22">Hendrikse NH</searchLink>; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Eersels+JLE%22">Eersels JLE</searchLink>; Precirix NV/SA, Brussels, Belgium.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Everaert+H%22">Everaert H</searchLink>; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Gykiere+P%22">Gykiere P</searchLink>; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Devoogdt+N%22">Devoogdt N</searchLink>; Precirix NV/SA, Brussels, Belgium.; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Raes+G%22">Raes G</searchLink>; Precirix NV/SA, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; and.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Lahoutte+T%22">Lahoutte T</searchLink><br /><searchLink fieldCode="AU" term="%22Keyaerts+M%22">Keyaerts M</searchLink>; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; marleen.keyaerts@vub.be.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220217410%22">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</searchLink> [J Nucl Med] 2021 Aug 01; Vol. 62 (8), pp. 1097-1105. <i>Date of Electronic Publication: </i>2020 Dec 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Society+of+Nuclear+Medicine%22">Society of Nuclear Medicine </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0217410 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1535-5667 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201615505%22">01615505 </searchLink><i>NLM ISO Abbreviation: </i>J Nucl Med
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33277400
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2967/jnumed.120.255679
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1097
    Titles:
      – TitleFull: Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: D'Huyvetter M
      – PersonEntity:
          Name:
            NameFull: Vos J
      – PersonEntity:
          Name:
            NameFull: Caveliers V
      – PersonEntity:
          Name:
            NameFull: Vaneycken I
      – PersonEntity:
          Name:
            NameFull: Heemskerk J
      – PersonEntity:
          Name:
            NameFull: Duhoux FP
      – PersonEntity:
          Name:
            NameFull: Fontaine C
      – PersonEntity:
          Name:
            NameFull: Vanhoeij M
      – PersonEntity:
          Name:
            NameFull: Windhorst AD
      – PersonEntity:
          Name:
            NameFull: Aa FV
      – PersonEntity:
          Name:
            NameFull: Hendrikse NH
      – PersonEntity:
          Name:
            NameFull: Eersels JLE
      – PersonEntity:
          Name:
            NameFull: Everaert H
      – PersonEntity:
          Name:
            NameFull: Gykiere P
      – PersonEntity:
          Name:
            NameFull: Devoogdt N
      – PersonEntity:
          Name:
            NameFull: Raes G
      – PersonEntity:
          Name:
            NameFull: Lahoutte T
      – PersonEntity:
          Name:
            NameFull: Keyaerts M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2021 Aug 01
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1535-5667
          Numbering:
            – Type: volume
              Value: 62
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
              Type: main
ResultId 1